| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/15/2002 | CN1348815A Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use |
| 05/15/2002 | CN1348809A Dressed plaster for treating Bell's palsy and its prepn |
| 05/15/2002 | CN1348794A Sobering-up Chinese medicine |
| 05/15/2002 | CN1348763A Medicine composite for preventing or treaitng diseases relating to IL-12 over growth |
| 05/15/2002 | CN1084748C Aminomethyl-2,3,8,9-terahydro-7H-1,4,-dioxino [2,3-e]-indol-8-ones and derivatives |
| 05/15/2002 | CN1084747C Azolobenzazepine derivs, as neurological active agents |
| 05/15/2002 | CN1084744C N-substituted azaheterocyclic compounds |
| 05/15/2002 | CN1084743C 毒蕈碱拮抗剂 Muscarinic antagonist |
| 05/15/2002 | CN1084631C Powder medicine made of traditional Chinese medicine and western medicine for treating toothache, and prepn. method therefor |
| 05/15/2002 | CN1084619C Process for preparing medicine composition |
| 05/15/2002 | CN1084618C Use of serotonin antagonists (5HT3) for treatment disease |
| 05/14/2002 | US6388077 Spiro compounds |
| 05/14/2002 | US6387941 Antiserotonine agents |
| 05/14/2002 | US6387940 Heterocyclylmethyl-substituted pyrazole derivatives |
| 05/14/2002 | US6387937 Indole derivatives |
| 05/14/2002 | US6387936 Combinations of riluzole and levodopa for the treatment of Parkinson's disease |
| 05/14/2002 | US6387932 Somatostatin agonists |
| 05/14/2002 | US6387930 Antiarthritic agents; antiallergens; skin disorders; inflammatory bowel disorders |
| 05/14/2002 | US6387925 Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions |
| 05/14/2002 | US6387920 Isoxazole compounds; for treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, alzheimer's disease |
| 05/14/2002 | US6387919 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 05/14/2002 | US6387917 Nasal administering |
| 05/14/2002 | US6387916 Administering to humans, animals |
| 05/14/2002 | US6387914 Providing sedative-hypnotic treatment by administering barbiturate derivative compound |
| 05/14/2002 | US6387899 Antiserotonine agents; antidepressants |
| 05/14/2002 | US6387898 Treatment for CNS injuries |
| 05/14/2002 | US6387897 Preferentially substituted calcium channel blockers |
| 05/14/2002 | US6387895 Bone disorders; cardiovascular disorders |
| 05/14/2002 | US6387892 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| 05/14/2002 | US6387674 Has activity against betal amyloid 1-42 protein in beta sheet conformation; treatment of alzheimer's disease amyloidosis, atherosclerosis, and creutzfeld-jakob disease |
| 05/14/2002 | US6387616 Torsin, torsin genes, and methods of use |
| 05/14/2002 | US6387403 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 05/14/2002 | US6387389 Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use |
| 05/14/2002 | US6387364 Methods of healing wounds and fibrotic disorders using IL-10 |
| 05/14/2002 | CA2260898C Phosphinate based inhibitors of matrix metalloproteases |
| 05/14/2002 | CA2105071C Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| 05/14/2002 | CA2075876C Arylethylamines derivatives, process for their preparation and pharmaceutical compositions holding same |
| 05/14/2002 | CA2060815C Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes and 3-aminochr omanes |
| 05/14/2002 | CA2033418C Pharmaceutical preparation for oral administration in fluid form |
| 05/10/2002 | WO2002036829A2 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 05/10/2002 | WO2002036816A2 Method of determining susceptibility to diseases |
| 05/10/2002 | WO2002036792A2 Dna expression vectors |
| 05/10/2002 | WO2002036741A2 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/10/2002 | WO2002036634A2 Gene regulation therapy involving ferritin |
| 05/10/2002 | WO2002036627A2 Interferons, uses and compositions related thereto |
| 05/10/2002 | WO2002036605A2 Estrone-derivatives having cytoprotective activity |
| 05/10/2002 | WO2002036599A1 Thieno[2,3-c]isoquinolines for use as inhibitors of parp |
| 05/10/2002 | WO2002036596A2 CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
| 05/10/2002 | WO2002036590A1 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives |
| 05/10/2002 | WO2002036586A1 N-type calcium channel antagonists for the treatment of pain |
| 05/10/2002 | WO2002036581A1 Radiopharmaceuticals for diagnosing alzheimer's disease |
| 05/10/2002 | WO2002036577A1 Quinazoline derivatives and drugs |
| 05/10/2002 | WO2002036576A1 Phthalazinone derivatives |
| 05/10/2002 | WO2002036573A2 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
| 05/10/2002 | WO2002036569A1 N-type calcium channel antagonists for the treatment of pain |
| 05/10/2002 | WO2002036567A1 N-type calcium channel antagonists for the treatment of pain |
| 05/10/2002 | WO2002036565A1 Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 05/10/2002 | WO2002036562A2 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| 05/10/2002 | WO2002036560A1 Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis |
| 05/10/2002 | WO2002036556A2 Acylaminoalkyl-substituted benzenesulfonamide derivatives |
| 05/10/2002 | WO2002036555A1 Sulfamides as gamma-secretase inhibitors |
| 05/10/2002 | WO2002036554A2 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis |
| 05/10/2002 | WO2002036546A2 Alkynyl amides and their therapeutic applications |
| 05/10/2002 | WO2002036543A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 05/10/2002 | WO2002036542A1 Crystalline forms of venlafaxine hydrochloride |
| 05/10/2002 | WO2002036170A2 Vector system for transducing the positive neurons |
| 05/10/2002 | WO2002036169A2 Methods and compositions for enhanced delivery of bioactive molecules |
| 05/10/2002 | WO2002036166A2 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
| 05/10/2002 | WO2002036162A2 Compositions for treatment of ocular neovascularization and neural injury |
| 05/10/2002 | WO2002036151A2 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | WO2002036148A2 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death |
| 05/10/2002 | WO2002036140A2 Use of a preparation of cimicifuga racemosa |
| 05/10/2002 | WO2002036125A1 The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache |
| 05/10/2002 | WO2002036123A2 New treatments for restless legs syndrome |
| 05/10/2002 | WO2002036118A2 Heterocyclic derivatives useful as pharmaceutical agents |
| 05/10/2002 | WO2002036116A2 Tripeptidyl peptidase inhibitors |
| 05/10/2002 | WO2002036115A1 Sulphonamides for the treatment of central nervous system diseases |
| 05/10/2002 | WO2002036108A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 05/10/2002 | WO2002036107A2 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 05/10/2002 | WO2002036105A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 05/10/2002 | WO2002036099A1 Controlled release hydrocodone formulations |
| 05/10/2002 | WO2002036072A2 Method for short-term and long-term drug dosimetry |
| 05/10/2002 | WO2002036071A2 Method of treating and preventing migraine headaches |
| 05/10/2002 | WO2002035942A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/10/2002 | WO2002016381A3 Composition and method for inhibiting platelet aggregation |
| 05/10/2002 | WO2002008200A3 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 05/10/2002 | WO2001097813A3 Highly concentrated stable meloxicam solutions |
| 05/10/2002 | WO2001097809A3 Method of treating cardiovascular disease using rapamycin |
| 05/10/2002 | WO2001093890B1 Botulinum toxin implant |
| 05/10/2002 | WO2001093827B1 Neurotoxin implant |
| 05/10/2002 | WO2001089498A3 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS |
| 05/10/2002 | WO2001082946A3 Neuroprotective compositions |
| 05/10/2002 | WO2001082919A3 Methods of and compounds for inhibiting calpains |
| 05/10/2002 | WO2001072288A3 Use of cdp-choline for the treatment of alcohol withdrawal syndrome |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001068063A3 Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 05/10/2002 | WO2001066742A3 G-protein coupled receptors |
| 05/10/2002 | WO2001066594A3 Human protein kinases and protein kinase-like enzymes |
| 05/10/2002 | WO2001064879A3 G-proteins coupled receptor related polypeptides |
| 05/10/2002 | WO2001064214A3 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |